ICCM is trading 12.8% up at $6.09 in pre-market, extending a sharp rally following a June 17 announcement highlighting FDA-backed adoption of its tumor-freezing technology.
- The move reflects a rapid re-rating of the company's commercial potential, which recently drove the stock from $2.13 to the mid-$6 range.
- The significant price action comes despite the company reporting modest annual sales of approximately $3.4 million.